Radiopharmaceuticals in metastatic bone pain palliation
Main Article Content
Abstract
The paper reviews the current status of the use of radiopharmaceuticals in the treatment of pain caused by bone metastases putting emphasis on the doses used, the effectiveness and safety of developing and on-the-market products. The convenience of the routine use in the case of multiple metastasis is established, since the results are adequate and the risks acceptable. The doses and the adverse effects are considered. The importance of the costs is given, as well as the availability of radionuclides. Reference is made to both the practice in developed countries and those with limited resources. The Cuban experience and the perspectives of the use in our country are pointed out.
Article Details
How to Cite
García, E. (1). Radiopharmaceuticals in metastatic bone pain palliation. Nucleus, (52). Retrieved from http://nucleus.cubaenergia.cu/index.php/nucleus/article/view/572
Section
Ciencias Nucleares
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista. Bajo esta licencia el autor será libre de:
- Compartir — copiar y redistribuir el material en cualquier medio o formato
- Adaptar — remezclar, transformar y crear a partir del material
- El licenciador no puede revocar estas libertades mientras cumpla con los términos de la licencia
Bajo las siguientes condiciones:
- Reconocimiento — Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
- NoComercial — No puede utilizar el material para una finalidad comercial.
- No hay restricciones adicionales — No puede aplicar términos legales o medidas tecnológicas que legalmente restrinjan realizar aquello que la licencia permite.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
La Revista Nucleus solo aceptará contribuciones que no hayan sido previamente publicados y/o procesados, por otra publicación. Cualquier violación ese sentido será considerada una falta grave por parte del autor principal lo cual será objeto valoración por parte del Consejo Editorial, el cual dictaminará al respecto.
References
1. CAPOCACCIA R, COLONNA M, CORAZZIARI I, et. al. Measuring cancer prevalence in Europe: the EUROPREVAL Project. Annals of Oncology. 2002; 13(6): 831- 839.
2. POLEDNAK AP. Estimating the prevalence of cancer in the United States. Cancer. 1997; 80(1): 136-41.
3. MERCADANTE S. Malignant bone pain: pathophysiology and treatment. Pain. 1997; 69(1-2): 1-18.
4. ROODMAN GD. Mechanisms of Bone Metastasis. N. Engl. J. Med. 2004; 350(16):1655-64.
5. JANJAN N. Bone metastases: approaches to management. Semin Oncol. 2001; 28(4 Suppl 11): 28-34.
6. DIEL IJ. What do patients with metastatic bone pain need?. Eur J Cancer Suppl. 2006; 4(8): 1- 3.
7. FINLAY IG, MASON MD, SHELLEY M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005; 6(6): 392-400.
8. ENRIQUE O, ZHONGYUN P, PARMA EP, et. al. Efficacy and toxicity of 153Sm-EDTMP in the palliative treatment of painful bone metastases. World. J. Nucl. Med. 2002; 1(1): 21-27.
9. FETTICH J, PADHY A, NAIR N, et. al. Comparative clinical efficacy and safety of 32P and 89Sr in the palliative treatment of metastatic Bone Pain: results of an IAEA coordinated research project. World. J. Nucl. Med. 2003; 2(3): 226-231.
10. CHAKRABORTY S, DAS T, UNNI PR, et. al. 177Lu labelled polyaminopshonates as potential agents for bone pain palliation. Nucl. Med. Communications. 2002; 23: 67-74.
11. LIEPE K, KROPP J, RUNGE R, KOTZERKE J. Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. British J Cancer. 2003; 89(4): 625-629
12. LEONDI AH, SOUVATZOGLOU MA, RAPTI AS, et. al. Palliative treatment of painful disseminated bone metastases with 186 Rhenium-HEDP in patients with lung cancer. Q J Nucl Med. 2004; 48(3): 211-9.
13. BISHAYEE A, RAO DV, SRIVASTAVA C, et. al. Marrow-sparing effects of 117mSn (4+) diethylenetriaminepentaacetic acid for radionuclide therapy of bone cancer. J. Nucl. Med. 2000; 41(3): 2043-2050.
14. NILSSON S, FRANZEN L, PARKER C, et. al. Alfa-emitting Radium-223: two years follow up from a randomized phase II study in patients with bone metastases from hormone refractory prostate cancer. Eur J Cancer Suppl. 2009; 7(2): 411.
15. SERAFINI AN. Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis. Q J Nucl Med 2001; 45(1): 91-9.
16. HENK G. VAN DER POEL. Radionuclide Treatment in Metastasized Prostate Cancer. EAU - EBU Update Series. 2007; 5(3): 113-125.
17. HAN SH, de KLERK JMN, TAN S, et. al. The Placorhen Study: a double-blind, placebo controlled, randomized radionuclide study with 186Re-etidronate in hormono-resistant prostate cancer patients with painful bone metastases. J. Nucl. Med. 2002; 43(9): 1150-1156.
18. FRIEDELL HL, STORAASLI JP. The use of radioactive phosphorus in the treatment of carcinoma of the breast with widespread metastases to the bone. Am J Roentgenol Radium Ther. 1950; 64(4):559-75.
19. SEVILLA A, SALGADO L, FONSECA AT, VIEIRA MR. Is early 89Sr-Therapy useful in prostate cancer patient with bone metastasis?. World. J. Nucl. Med. 2002; 1(Suppl 2): 276.
20. FERRETTI G., POVOLATO M., BISSSOLI S. 89SrCl and 153Sm-EDTMP radiometabolic treatment of metastatic bone pain (MBP) in prostate cancer (PC): our experience. Alasbimn Journal. 2002; 5 (17). Special Issue: World Congress of Nuclear Medicine.
21. NAIR N. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases. J. Nucl. Med. 1999; 40(2): 256-261.
22. SINZINGER H, WEISS K, GRANEGGER S, HAJEK C. Repeated low-dose vs. single higt-dose 153Sm-EDTMP treatment. Advantages and disadvantages . Alasbimn Journal. 2002; 5(17). Special Issue: World Congress of Nuclear Medicine.
23. SRIVASTAVA SC, ATKINS HL, KRISHNAMURTHY GT, et. al. Treatment of metastatic bone pain with tin-117m stannic diethylenetriamine pentaacetic acid: a phase I/II clinical stud. Clin. Cancer Res. 1998; 4(1): 61-68.
24. SILBERSTEIN EB, BUSCOMBE JR, MC.EWANS A, TAYLOR AT. Society of nuclear medicine procedure guideline for palliative treatment of painful bone metastases. Society of nuclear medicine procedure. Guidelines manual. 2003. p. 145-153.
25. COOK GJR. Skeletal metastases: what is the future role for nuclear medicine?. Eur J Nucl Med Mol Imaging. 2009; 36(11):1803-1806.doi: 10.1007/S00259-009-1240-8.
26. PORTILLA I, ALSINA S de la C. OLIVA JP, et. al. P-32 en el tratamiento de las metástasis óseas por carcinoma prostático. Rev Cubana Oncol. 2000; 16(1): 44 -7.
2. POLEDNAK AP. Estimating the prevalence of cancer in the United States. Cancer. 1997; 80(1): 136-41.
3. MERCADANTE S. Malignant bone pain: pathophysiology and treatment. Pain. 1997; 69(1-2): 1-18.
4. ROODMAN GD. Mechanisms of Bone Metastasis. N. Engl. J. Med. 2004; 350(16):1655-64.
5. JANJAN N. Bone metastases: approaches to management. Semin Oncol. 2001; 28(4 Suppl 11): 28-34.
6. DIEL IJ. What do patients with metastatic bone pain need?. Eur J Cancer Suppl. 2006; 4(8): 1- 3.
7. FINLAY IG, MASON MD, SHELLEY M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005; 6(6): 392-400.
8. ENRIQUE O, ZHONGYUN P, PARMA EP, et. al. Efficacy and toxicity of 153Sm-EDTMP in the palliative treatment of painful bone metastases. World. J. Nucl. Med. 2002; 1(1): 21-27.
9. FETTICH J, PADHY A, NAIR N, et. al. Comparative clinical efficacy and safety of 32P and 89Sr in the palliative treatment of metastatic Bone Pain: results of an IAEA coordinated research project. World. J. Nucl. Med. 2003; 2(3): 226-231.
10. CHAKRABORTY S, DAS T, UNNI PR, et. al. 177Lu labelled polyaminopshonates as potential agents for bone pain palliation. Nucl. Med. Communications. 2002; 23: 67-74.
11. LIEPE K, KROPP J, RUNGE R, KOTZERKE J. Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. British J Cancer. 2003; 89(4): 625-629
12. LEONDI AH, SOUVATZOGLOU MA, RAPTI AS, et. al. Palliative treatment of painful disseminated bone metastases with 186 Rhenium-HEDP in patients with lung cancer. Q J Nucl Med. 2004; 48(3): 211-9.
13. BISHAYEE A, RAO DV, SRIVASTAVA C, et. al. Marrow-sparing effects of 117mSn (4+) diethylenetriaminepentaacetic acid for radionuclide therapy of bone cancer. J. Nucl. Med. 2000; 41(3): 2043-2050.
14. NILSSON S, FRANZEN L, PARKER C, et. al. Alfa-emitting Radium-223: two years follow up from a randomized phase II study in patients with bone metastases from hormone refractory prostate cancer. Eur J Cancer Suppl. 2009; 7(2): 411.
15. SERAFINI AN. Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis. Q J Nucl Med 2001; 45(1): 91-9.
16. HENK G. VAN DER POEL. Radionuclide Treatment in Metastasized Prostate Cancer. EAU - EBU Update Series. 2007; 5(3): 113-125.
17. HAN SH, de KLERK JMN, TAN S, et. al. The Placorhen Study: a double-blind, placebo controlled, randomized radionuclide study with 186Re-etidronate in hormono-resistant prostate cancer patients with painful bone metastases. J. Nucl. Med. 2002; 43(9): 1150-1156.
18. FRIEDELL HL, STORAASLI JP. The use of radioactive phosphorus in the treatment of carcinoma of the breast with widespread metastases to the bone. Am J Roentgenol Radium Ther. 1950; 64(4):559-75.
19. SEVILLA A, SALGADO L, FONSECA AT, VIEIRA MR. Is early 89Sr-Therapy useful in prostate cancer patient with bone metastasis?. World. J. Nucl. Med. 2002; 1(Suppl 2): 276.
20. FERRETTI G., POVOLATO M., BISSSOLI S. 89SrCl and 153Sm-EDTMP radiometabolic treatment of metastatic bone pain (MBP) in prostate cancer (PC): our experience. Alasbimn Journal. 2002; 5 (17). Special Issue: World Congress of Nuclear Medicine.
21. NAIR N. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases. J. Nucl. Med. 1999; 40(2): 256-261.
22. SINZINGER H, WEISS K, GRANEGGER S, HAJEK C. Repeated low-dose vs. single higt-dose 153Sm-EDTMP treatment. Advantages and disadvantages . Alasbimn Journal. 2002; 5(17). Special Issue: World Congress of Nuclear Medicine.
23. SRIVASTAVA SC, ATKINS HL, KRISHNAMURTHY GT, et. al. Treatment of metastatic bone pain with tin-117m stannic diethylenetriamine pentaacetic acid: a phase I/II clinical stud. Clin. Cancer Res. 1998; 4(1): 61-68.
24. SILBERSTEIN EB, BUSCOMBE JR, MC.EWANS A, TAYLOR AT. Society of nuclear medicine procedure guideline for palliative treatment of painful bone metastases. Society of nuclear medicine procedure. Guidelines manual. 2003. p. 145-153.
25. COOK GJR. Skeletal metastases: what is the future role for nuclear medicine?. Eur J Nucl Med Mol Imaging. 2009; 36(11):1803-1806.doi: 10.1007/S00259-009-1240-8.
26. PORTILLA I, ALSINA S de la C. OLIVA JP, et. al. P-32 en el tratamiento de las metástasis óseas por carcinoma prostático. Rev Cubana Oncol. 2000; 16(1): 44 -7.